Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2009

View Archived Issues

Oxcarbazepine reduces pain in Parkinson's disease patients

CD40L gene therapy shows promise in urothelial bladder cancer trial

Calixa Therapeutics announces successful completion of phase I study of CXA-101

Endo completes acquisition of Indevus

Toyama and Eisai to conduct additional study for T-614 and resubmit NDA

Shire reviews Q4 activities and looks ahead to upcoming milestones

Novel histamine H3 receptor antagonists claimed in AstraZeneca patent

Ono Pharmaceutical prepares and tests novel prostanoid DP receptor antagonists

Advaxis updates phase I trial survival data for ADXS-11-001

Orexo announces phase IIa data on OX-914 in allergic rhinitis

Celsion receives orphan drug designation for ThermoDox in liver cancer

Epiphany Biosciences to file IND to study valomaciclovir adjunctive therapy in MS

Morphotek and Eisai commence FDA SPA phase III farletuzumab trial

Genfit acquires type 2 diabetes and obesity program from Merck Sante

Novel antiviral candidate for the treatment of chronic hepatitis C is discovered

Radius initiates phase IIa RAD-1901 trial in menopausal hot flashes

Rexahn receives FDA approval to begin phase II trials for Archexin in pancreatic cancer

Dual inhibitor of Fms/Kit described by Plexxikon for the treatment of autoimmune conditions

Avexa reaches 16-week evaluation point in phase III trial of apricitabine in HIV

WAY-262611 acts as a Wnt beta-catenin agonist, increases bone formation in osteoporosis model

PF-0419789, mutant B-Raf inhibitor, synthesized at Pfizer

ACT-077825 generally well tolerated, decreases blood pressure in first-in-human study

DSMB recommends continuation of phase III trial of Vical's Allovectin-7

Vantia presents update on preclinical and clinical development portfolios

Syndax Pharmaceuticals describes sirtuin modulators for cancer treatment

Lilly presents novel gamma-secretase inhibitors

Novel histamine H1 receptor antagonists described by GlaxoSmithKline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...